Unusual discordant responses in two multiple myeloma patients during bortezomib treatment

Onkologie

Volumn 31, Issue 1-2, 2008, Pages 45-47

  Pirrotta, M T ^a   Gozzetti, A ^a   Cerase, A ^b   Bucalossi, A ^a   Bocchia, M ^a   Defina, M ^a   Lauria, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Bortezomib; Extramedullary myeloma localization; Myeloma

Indexed keywords

BORTEZOMIB; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; IMMUNOGLOBULIN G; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CASE REPORT; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CEREBELLUM; DEXAMETHASONE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MENINGES; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLASMA CELLS; PYRAZINES; SKIN;

EID: 39149105933     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112217     Document Type: Article

References (8)

1. Kaufman JL, Lonial S: Proteasome inhibition: novel therapy for multiple myeloma. Onkologie 2006;29:162-168.
2. Ali R, Ozkalemkas F, Ozkan A, Ozkocaman V, Ozcelik T, Ozan U, Kurt M, Tunali A: Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Leuk Res 2007;31:1153-1155.
3. Cibeira MT, Rosiñol L, Ramiro L, Esteve J, Torrebadell M, Bladé J: Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006;76:405-408.
4. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R: Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogenic transplantation. Haematologica 2005;90:278-279.
5. Pantelidou D, Tsatalas C, Margaritis D, Anastasiadis AG, Kaloutsi V, Argyropoulou P, Prassopoulos P, Bourikas G: Successful treatment of lymph node extramedullary plasmacytoma with bortezomib. Ann Hematol 2006;85:188-190.
6. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumours with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-2121.
7. Schwartz R, Davidson T: Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology 2004;18:14-21.
8. Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E: Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832-836.